Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 408

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 408
---
20 trading days preceding

May 30, 2024, May 31, 2023 and June 6, 2022, respectively .

| SANOFIFORM 20-F2024 | F-53 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

The table below sets forth the expense recognized for each plan:

| (€ million)                      | 2024 | 2023 | 2022 |
| Expense recognized               |   45 |   52 |   39 |
| of which employer’s contribution |   11 |   12 |   11 |

D.15.4. Repurchase of Sanofi shares The Annual General Meetings of Sanofi shareholders held on April 30, 2024, May 25, 2023 and May 3, 2022 each authorized a share repurchase program for a period of 18months . The following repurchases have been made under those programs:

| (in number of sharesand € million)Year of authorization |      2024 |                 |      2023 |                 |      2022 |     |
| Numberof shares                                         |     Value | Numberof shares |     Value | Numberof shares |     Value |     |
| 2024 program                                            |         — |               — |         — |               — |         — |   — |
| 2023 program                                            | 3,215,460 |             302 | 2,584,540 |             230 |         — |   — |
| 2022 program                                            |         — |               — | 4,000,204 |             363 | 1,510,000 | 137 |
| 2021 program                                            |         — |               — |         — |               — | 3,976,992 | 360 |

D.15.5. Reductions in share capital Reductions in share capital for the accounting periods presented are described in the table included at Note D.15.1. above. Those reductions have no impact on shareholders’ equity. D.15.6. Currency translation differences Currency translation differences comprise the following:

| (€ million)                               |  2024 | 2023 |  2022 |
| Attributable to equity holders of Sanofi  | 2,408 |  -31 | 1,499 |
| Attributable to non-controlling interests |   -17 |  -37 |   -37 |
|